Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 40 results found. Search for [ Covishield ]

Results 1 to 21 of 40
PB Jayakumar & Joe C Mathew
October 22, 2020
Serum has floated a new company Serum Institute Life Sciences (SILS) that will exclusively focus on developing, producing and supplying pandemic vaccines


BusinessToday.In
October 19, 2020
Presently, there are around 40 different coronavirus vaccines in various stages of human clinical trials, comprising one being developed by Oxford University and AstraZeneca, which is already in an advanced stage of testing


BusinessToday.In
October 3, 2020
COVID-19 vaccine: A principal investigator from a trial site in Maharashtra said that they are expecting to finish enrolling the participants within the next two months after which they will be monitored for the vaccine's efficacy


BusinessToday.In
September 20, 2020
AstraZeneca's trial blueprint says that its goal is to develop a vaccine with 50 per cent effectiveness


BusinessToday.In
September 19, 2020
The final clinical trial of coronavirus vaccine by Oxford University and being manufactured by the Serum Institute of India (SII) will begin at the Sassoon General Hospital in Pune from Monday


BusinessToday.In
September 15, 2020
COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief


BusinessToday.In
September 12, 2020
DCGI VG Somani in his order also asked Serum Institute to suspend any new recruitment in Phase 2 and 3 clinical trials until further notice; SII also need to increase safety monitoring of test subjects vaccinated under trials so far


BusinessToday.In
September 12, 2020
The DCGI also asked Serum Institute to increase the safety monitoring of the test subjects vaccinated under the trials so far, and submit the plan and report


BusinessToday.In
September 11, 2020
Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report


BusinessToday.In
September 9, 2020
\"We are going by DCGI's direction and so far were not told to pause the trials. If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocols,\" says Serum Institute of India in response to show-cause notice issued by the DCGI


PB Jayakumar
September 9, 2020
Serum has also started manufacturing the vaccine, targeting to use in India and 92 other countries upon completion of trials and regulatory clearances


Rajeev Dubey & Manoj Sharma
September 9, 2020
\"AstraZeneca has paused the trials due to some unrelated issue with a patient in the UK, and we'll have to wait for AstraZeneca to explain what happened but this is not vaccine-related,\" says Poonawalla


BusinessToday.In
August 28, 2020
Coronavirus vaccine: The market for coronavirus vaccine in India could potentially be $6 billion in terms of sales for the coming three years


BusinessToday.In
August 27, 2020
Coronavirus vaccine news update: Let us respect the process and stay patient for two months, all the relevant data will be published soon, said Poonawalla


BusinessToday.In
August 26, 2020
Stock market update for upcoming week: 5 things to know before Thursday's opening bell


BusinessToday.In
August 26, 2020
Coronavirus vaccine update: Phase 2 trials of Oxford coronavirus vaccine, being manufactured by Serum Institute of India (SII), have begun in India


BusinessToday.In
New Delhi, August 25, 2020
Kalyan Jewellers files DRHP for Rs 1,750 crore IPOHome-grown jewellery maker Kalyan Jewellers India on Monday filed the draft prospectus for Rs 1,750 crore initial public offer (IPO). The gold retailer, backed by private equity firm Warburg Pincus, has filed its draft red herring prospectus (DRHP) with market regulator Securities and Exchange Board of India (Sebi) for listing of its share on BSE and NSE. The exact timeline of the IPO, issue size and price band of shares are yet to be ascertai...


Reuters
August 25, 2020
The vaccine candidate is one of nearly 30 being tested in human clinical trials globally and lags candidates from AstraZeneca, Pfizer and Moderna that are in late-stage studies


PTI
August 25, 2020
Serum Institute of India has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, developed by the University of Oxford


BusinessToday.In
New Delhi, August 24, 2020
India could get its first COVID vaccine in 73 days according to senior official at Serum Institute. Covishield has been fast tracked by the govt. The Centre has already indicated to SII that it will directly procure the vaccines and is planning to immunise Indians for free. Watch the video for more.Also Read: Metro services may resume from September 1, reopening of school unlikely


PAGES 1 OF 2  12